Last edition
News about "vedolizumab"
Samsung Bioepis Partners with Sandoz for Next-Gen Biosimilar Candidates
Samsung Bioepis has partnered with Sandoz to develop and commercialise up to five biosimilar candidates, including SB36 (vedolizumab), across global markets, excluding select Asian regions, strengthening its pipeline in immunology and oncology.
Vedolizumab | 19/03/2026 | By News Bureau
Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar
Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.
Vedolizumab | 06/08/2025 | By Dineshwori | 269
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy